Fairvalue-Calculator Fairvalue-Calculator
EN DE

AlzeCure Pharma AB (ALZCUR) Fair Value & Analysis

Healthcare · SE · Market cap 155M SEK

Pricekr 3.62
Fair Valuekr 1.29
Upside-64.4%
Quality95/100
Evidence: Low Range kr 0.9700 – kr 1.61

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

AlzeCure Pharma AB (ALZCUR) currently trades at kr 3.62, while our model-based Fair Value estimate is kr 1.29 — implying the stock looks roughly 64.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pain indications; and ACD137 negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications, which is in preclinical phase. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is AlzeCure Pharma AB (ALZCUR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 1.29 versus a price of kr 3.62 — about −64% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ALZCUR?
Our 21-model fair value for AlzeCure Pharma AB is kr 1.29 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 3.62.
What is the quality score of ALZCUR?
AlzeCure Pharma AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.